צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים: Genprex, Inc. (GNPX)

Genprex, Inc. relies on patent protection for diabetes and lung cancer treatments, ensuring stable demand and margins. This revenue growth chart over the last 12 months YoY confirms the development trend, where the 0.00 mark serves as the current indicator. High barriers to entry in the gene therapy niche and a shortage of effective solutions create opportunities for R&D licensing by global behemoths.
Genprex, Inc - פילוחים אנליטיים ומדדי מפתח (GNPX)

Genprex, Inc. (GNPX) faces significant capital pressure due to high development costs for its lung cancer gene therapy. This metric captures the percentage change in revenue over a rolling year, neutralizing timing gaps between quarterly reports. It is critical for investors to correlate revenue growth rates with the cash burn rate. A stable trend confirms the commercial viability of the technologies. Analyzing the TTM revenue growth YoY allows for an assessment of the asset's operational resilience.